A5016319509- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Hepatitis C virus research
- Ferroptosis and cancer prognosis
- Hepatitis B Virus Studies
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Lymphatic System and Diseases
- Cancer-related molecular mechanisms research
- Nutrition and Health in Aging
- Angiogenesis and VEGF in Cancer
- Abdominal Trauma and Injuries
- Renal Transplantation Outcomes and Treatments
- MRI in cancer diagnosis
- Pancreatitis Pathology and Treatment
- Circular RNAs in diseases
- Cancer Genomics and Diagnostics
- COVID-19 Impact on Reproduction
- Inflammatory Biomarkers in Disease Prognosis
- RNA modifications and cancer
- Lipid metabolism and disorders
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Cancer, Lipids, and Metabolism
University of Modena and Reggio Emilia
2020-2024
Policlinico di Modena
2021-2024
Associazione Italiana Sclerosi Multipla
2023
This study examined the association between dynamic angiopoietin-2 assessment and COVID-19 short- long-term clinical course. We included consecutive hospitalized patients from 1 February to 31 May 2020 with laboratory-confirmed 2 Italian tertiary referral centers (derivation cohort, n = 187 patients; validation 62 patients). Serum biomarker levels were measured by sandwich enzyme-linked immunosorbent assay. Lung tissue 9 was stained for angiopoietin-2, Tie2, CD68, CD34. Cox model used...
To the editor, Liver transplantation (LT) is only therapeutic option for both HCC and cirrhosis. Despite careful patient selection, HCC-R_LT occurs in as much 20%, often characterized by an aggressive clinical course high mortality. We therefore designed a proof-of-concept study aimed to analyze safety of combination therapy with nivolumab bevacizumab patients HCC-R_LT, whose tumor progressed most cases while on sorafenib therapy. In particular, we focused risk rejection overall survival...
Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of patients. We analyzed clinical, histopathological, and biological features patients with to identify predictive factors associated cancer survival after LT.We retrospectively 441 who underwent in our center. Overall, 70 (15.8%) them developed HCC-R_LT. matched by age at transplant etiology non-recurrent A comparable cohort from Liver Transplant Centre Bologna...
The male/female ratio of patients with hepatocellular carcinoma (HCC) is often unbalanced towards the male sex, indicating a sex predisposition for HCC development. A possible explanation may be attributed to different hormonal statuses, including pro-inflammatory action androgens in men and protective effects oestrogen against excessive inflammation women. Although several studies have studied gene expression HCC, very few attempted identify features that could distinctive between female...
We evaluated SARS-CoV-2 antibody response in voluntary blood donors Italy at different timepoints. Immediately after lockdown easing, 908/25,657 (3.5%) had low IgG titers against nucleocapsid. In the next 2 years, increased despite few COVID-19 symptoms. On multivariate analysis, allergic rhinitis was associated with reduced risk for symptomatic COVID-19.
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Curative treatments are available to a minority patients, as HCC often diagnosed at an advanced stage. For patients with unresectable and multifocal HCC, tyrosine kinase inhibitor drugs (TKIs) only potential treatment option. Despite extensive research, predictors response these therapies remain elusive. This study aimed analyze biological histopathological characteristics treated TKIs, focusing on...
: We evaluated the relationship between neoangiogenic transcriptomic signature (nTS) and clinical symptoms, treatment outcomes, survival in hepatocellular carcinoma (HCC) patients.
Abstract Background & Aims Hepatocellular carcinoma (HCC) is characterized by high clinical and biological heterogeneity, depending on the extremely variable combinations of pathways, linked with immune mechanisms, neo‐angiogenesis, ECM remodeling, metabolism and/or hypoxia. We recently identified a 5‐genes neo‐angiogenic transcriptomic signature (TS), able to discriminate between “aggressive” HCCs (TS‐positive) from “bland” (TS negative), former having poor survival. The aim this study...
Abstract Recurrent hepatocellular carcinoma (HCC-R) after Liver Transplant (LT) is difficult to manage and often characterized by relevant aggressiveness extrahepatic localizations. Currently TKIs are the only therapeutic option, but results in term of overall survival (OS) progression-free disappointing. Immune checkpoint inhibitors association with recombinant humanized monoclonal antibody VEGF were be proved effective non-LT patients metastatic determining tumor stabilization improved...
e16634 Background: Recurrence of hepatocellular carcinoma after liver transplant (LT-HCC), affects ~40% patients. As LT-HCC drastically limits therapeutic options, combination drugs with different mechanism actions might be an attractive approach. Primary objective this MiHRCO (Milciclib and Half Regorafenib CO-administration) protocol (87/2019/COMP/MiHRCO) is to evaluate safety clinical activity (a tyrosine kinase inhibitor higher in aggressive HCC) Milciclib pan cyclin dependent activities...